Regeneron's Trading Volume Drops 34.37% to $333 Million Ranking 295th in Market Activity

On June 25, 2025, Regeneron's trading volume reached $333 million, a 34.37% decrease from the previous day, ranking 295th in the day's stock market activity. Regeneron's stock price fell by 0.38%.

Regeneron Pharmaceuticals has provided an update on their ongoing Phase 2 clinical study for REGN7544, an experimental monoclonal antibody designed to treat sepsis-induced hypotension. The study, which began on May 5, 2025, aims to evaluate the safety, tolerability, and efficacy of REGN7544 in adult patients with sepsis-induced hypotension. The primary focus is on its effects on blood pressure and vasopressor dosage. The study follows a randomized, double-blind, placebo-controlled design with quadruple masking, ensuring that participants, care providers, investigators, and outcomes assessors are all blinded. The latest update was submitted on June 23, 2025, and the study is still actively recruiting participants. This clinical update could potentially boost investor confidence in Regeneron, particularly if the results demonstrate the therapeutic potential of REGN7544 in treating sepsis-induced hypotension. The ongoing study positions Regeneron competitively within the pharmaceutical industry, especially in the sepsis treatment market.